Skip to main content
Access Bio, Inc. logo

Access Bio, Inc. — Investor Relations & Filings

Ticker · 950130 ISIN · KR8840090003 LEI · 335800Q5TV77F4L9Q648 KO Manufacturing
Open in API
Filings indexed 247 across all filing types
Latest filing 2020-03-26 Declaration of Voting R…
Country IN India
Listing KO 950130

About Access Bio, Inc.

https://accessbio.net/

Access Bio, Inc. is a company dedicated to the prevention and early diagnosis of infectious diseases through the research, development, and manufacturing of in vitro diagnostic solutions. Its portfolio includes rapid diagnostic tests (RDTs), immunochemical diagnostics, biosensors, and molecular diagnostic products. The company is recognized for commercializing high-quality tests to combat significant global health threats, including malaria, COVID-19, HIV, and HPV. With a large-scale manufacturing capacity, Access Bio distributes its products globally, serving as a key partner in global health, particularly in the fight against often-neglected diseases.

Recent filings

Filing Released Lang Actions
정기주주총회결과
Declaration of Voting Results & Voting Rights Announcements Classification · 1% confidence The document is titled '정기주주총회결과' (Annual General Meeting Results) and provides a detailed breakdown of the resolutions passed during the meeting, including financial statement approval, director re-elections, and remuneration limits. This is a formal declaration of the outcomes of a shareholder meeting, which fits the definition of a Declaration of Voting Results.
2020-03-26 Korean
감사보고서제출
Audit Report / Information Classification · 1% confidence The document is a regulatory filing titled '감사보고서 제출' (Submission of Audit Report) from Access Bio. It provides a summary of financial data, audit opinions, and key financial metrics (assets, liabilities, profit/loss) for the current and previous fiscal years. While it contains financial data, it is a standard regulatory disclosure format used in South Korea (DART system) to announce the receipt and submission of the audit report to the regulator, rather than the full annual report document itself. Therefore, it is classified as a Regulatory Filing (RNS). FY 2019
2020-03-18 Korean
주주총회소집공고
Proxy Solicitation & Information Statement Classification · 1% confidence The document is a 'Notice of Annual General Meeting' (주주총회소집공고) for Access Bio, Inc. It contains the meeting date, location, agenda items (approval of financial statements, election of directors, remuneration limits, and stock option grants), and detailed financial information (balance sheets and income statements) for the 18th fiscal year. This document is a formal notice sent to shareholders to provide information and request votes for the upcoming meeting, which fits the definition of a Proxy Solicitation & Information Statement.
2020-03-10 Korean
주주총회집중일개최사유신고
AGM Information Classification · 1% confidence The document is a formal regulatory filing submitted to the Korea Exchange (KRX) regarding the 'Reason for holding a General Meeting of Shareholders on a concentrated date'. It explains the scheduling constraints for the company's AGM. Since it is a specific regulatory disclosure regarding meeting logistics rather than the meeting materials themselves (AGM-R) or a proxy statement (PSI), it falls under the general regulatory filing category.
2020-02-24 Korean
매출액또는손익구조30%(대규모법인은15%)이상변동
Management Reports Classification · 1% confidence The document is a regulatory filing from Access Bio regarding a significant change in financial results (a 30% or more change in revenue or profit structure). This is a standard Korean regulatory disclosure (DART system) for preliminary earnings results. Since it provides the initial announcement of financial performance highlights rather than a full annual report or a transcript, it falls under the Earnings Release category.
2020-02-21 Korean
주주총회소집결의
AGM Information Classification · 1% confidence The document is a formal notice of a General Meeting of Shareholders (주주총회소집결의) for Access Bio. It outlines the date, location, agenda items (financial statement approval, director appointments, remuneration limits), and details regarding the board's resolution. This type of document is a standard proxy solicitation/information statement provided to shareholders to inform them of upcoming meeting details and agenda items.
2020-02-21 Korean

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.